Skip to content

High Fat Diet II on Weight Loss

Effect of High Saturated Fat No Starch Diet vs. Low Saturated Fat, Low Trans Fat, High Fiber Diet on Weight Loss and Markers of Atherosclerotic Cardiovascular Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00525850
Acronym
HFD
Enrollment
20
Registered
2007-09-06
Start date
2006-12-31
Completion date
2010-09-30
Last updated
2011-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

cardiovascular disease, weight loss

Brief summary

To evaluate two different diets and their effects on weight loss and measurements of several risk factors for cardiovascular disease. One diet will be a high saturated fat diet (HSFD) and the other is a low saturated fat diet (LSFD) that limits fat but especially saturated fat as red meat. All participants in this study must eat both diets as this is a randomized cross-over design.

Interventions

high saturated fat no starch diet

low calorie low saturated fat low trans fat high fiber diet

Sponsors

Christiana Care Health Services
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

In order to qualify, participants must have metabolic syndrome: * triglycerides greater than 150 mg/dL * blood pressure greater than 130 mmHg and/or diastolic blood pressure greater than 85 mmHg * fasting glucose greater than 110 mg/dL * waist circumference greater than 40 inches in men or 35 inches in women * reduced HDL less than 40 mg/dL in men and less than 50 mg/dL in women. Participants must be capable of performing symptom-limited maximal exercise capacity study. Blood and urine samples collected at baseline will be analyzed for CBC, serum glucose and electrolytes, hepatic panel and TSH.

Exclusion criteria

Participants will be excluded for any significant blood dyscrasia, fasting glucose greater than 200 mg/dL, creatine greater than 2 mg/dL, any significant electrolyte disorder, hepatic functions greater than two times normal or abnormal TSH.

Design outcomes

Primary

MeasureTime frame
Weight loss12 weeks

Secondary

MeasureTime frame
Brachial artery reactivity12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026